Compare AFLAC Incorporated (AFL) vs Nuwellis Inc (NUWE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AFLAC Incorporated vs Nuwellis Inc — how do they compare? AFLAC Incorporated trades at $121.41 (market cap $61.84B), while Nuwellis Inc trades at $2.84 (market cap $1.15M). The key difference: AFLAC Incorporated is far larger — about 53773.9× Nuwellis Inc's market cap, and AFLAC Incorporated pays a 2.01% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| AFL | NUWE | |
|---|---|---|
Market Cap | $61.84B | $1.15M |
Sector | Financials | Technology |
52-Week High | $121.49 | $558.26 |
52-Week Low | $98.09 | $3.05 |
Enterprise Value | $70.50B | -$662.47K |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aflac (AFL) trades at $121.49, up 0.5% with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a 25.32% net income margin and 16.47% ROE, though recent Q1 2026 earnings missed expectations. Analyst consensus is mixed with 28% buy ratings and a $113.57 price target below current levels. Recent developments include strong dividend performance and upcoming Q2 2026 results announcement on August 6, 2026.
The outlook remains cautiously optimistic with solid profitability and dividend stability, but faces headwinds from recent earnings misses and premium valuation pressure. Key opportunities include continued growth in Japan and U.S. markets, while risks involve medical cost inflation and uneven revenue trends. The stock's current premium to analyst targets suggests limited near-term upside potential.
NUWE trades at $3.29, up 4.44% today, but faces a bearish technical outlook with moving averages signaling a downtrend. The company reported a net loss of $17.52 million in 2025, with a negative net income margin of -217.22%, though it beat earnings expectations in two of the last three quarters. Recent news highlights expansion efforts, including new CEO Mike McCormick outlining strategic priorities and a $6 million public offering closed in June 2026 to support growth.
The outlook remains challenging due to persistent losses and high cash burn, but low valuation ratios like a P/E of 0.64 and P/B of 0.45 may attract value investors. Key risks include the need to achieve profitability and competitive pressures in the medical technology sector. Analyst sentiment is mixed with a 50% buy rating, suggesting cautious optimism amid fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
